Shixie Jiang
Assistant Professor/M.D.
- Gainesville FL UNITED STATES
- College of Medicine
Shixie Jiang studies the treatment of neuropsychiatric disorders in the acute medically ill, delirium diagnosis and management.
Contact More Open optionsBiography
Dr. Shixie Jiang is clinically trained in consultation-liaison psychiatry, with an emphasis on critical care psychiatry. He also specializes in delirium diagnosis, management, and prevention strategies. He currently work at UF Health Shands Hospital and provide consultation services to inpatient medical/surgical teams. Dr. Jiang's research focus is on developing new portable optical neuroimaging techniques for the study of delirium, particularly how delirium can cause incident dementias or worsening of pre-existing dementias.
Areas of Expertise
Articles
Delayed-Onset Psychosis Secondary to Tacrolimus Neurotoxicity After Lung Transplant: A Case Report and Systematic Review
Journal of the Academy of Consultation-Liaison PsychiatryMatthew Gunther, et. al
2023-09-29
Tacrolimus is the most common immunosuppressant used after transplant, yet it can result in moderate-to-severe neurotoxicity in up to 32% of patients. Signs of neurotoxicity can vary from mild (tremor or headache) to severe (posterior reversible encephalopathy syndrome or psychosis. Prompt recognition and management is needed to lead to symptom resolution.
Terminal Delirium
Annals of Long-Term CareShixie Jiang, et. al
2023-07-11
The majority of patients experience delirium in the last days of life. A systematic approach to management is essential to ensure a comfortable and peaceful death for the patient and their loved ones. Most patients develop hypoactive delirium with progressively decreasing levels of consciousness, but at least 10% to 25% of patients develop hyperactive delirium with agitation and distress.
A Retrospective Analysis of Guanfacine for the Pharmacological Management of Delirium
CureusShixie Jiang, et. al
2023-01-15
Delirium is a syndrome of acute brain failure that represents a change from an individual's baseline cognitive functioning characterized by deficits in attention and multiple aspects of cognition that fluctuate in severity over time. The symptomatic management of delirium's behavioral manifestations remains difficult. The alpha-2 agonists, dexmedetomidine and clonidine, are efficacious, but their potential cardiovascular adverse effects limit their utilization.
